Kastelein, John J.P.

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Leiter, L. A., Teoh, H., Kallend, D., Wright, R. S., Landmesser, U., Wijngaard, P. L. J., Kastelein, J. J. P., & Ray, K. K. (2019) · Diabetes Care

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 117

Hepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia

Sankatsing, R. R., Fouchier, S. W., de Haan, S., Hutten, B. A., de Groot, E., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersLiver Disease Diagnosis and Treatment

Cited by 106

Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms

Sofat, R., Hingorani, A. D., Smeeth, L., Humphries, S. E., Talmud, P. J., Cooper, J., Shah, T., Sandhu, M. S., Ricketts, S. L., Boekholdt, S. M., et al. (2010) · Circulation

Lipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

Cited by 104

Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis

Clee, S. M., Bissada, N., Miao, F., Miao, L., Marais, A. D., Henderson, H. E., Steures, P., McManus, J., McManus, B., LeBoeuf, R. C., et al. (2000) · Journal of Lipid Research

Lipid metabolism and disordersCholesterol and Lipid Metabolism

Cited by 101

Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

Raal, F., Durst, R., Bi, R., Talloczy, Z., Maheux, P., Lesogor, A., Kastelein, J. J. P., & on behalf of the ORION-5 Study Investigators (2024) · Circulation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 96

Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)

Bays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology

Lipid metabolism and disordersFatty Acid Research and Health

Cited by 94

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1

Landmesser, U., Haghikia, A., Leiter, L. A., Wright, R. S., Kallend, D., Wijngaard, P., Stoekenbroek, R., Kastelein, J. J., & Ray, K. K. (2021) · Cardiovascular Research

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 83

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week multicenter, randomized, double-blind, controlled trial

Huijgen, R., Abbink, E. J., Bruckert, E., Stalenhoef, A. F. H., Imholz, B. P. M., Durrington, P. N., Trip, M. D., Eriksson, M., Visseren, F. L. J., Schaefer, J. R., et al. (2010) · Clinical Therapeutics

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 80

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial

Nissen, S. E., Lincoff, A. M., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Ridker, P. M., Ray, K. K., McGuire, D. K., Mozaffarian, D., Koenig, W., et al. (2021) · JAMA Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 76

Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 → Cys) homozygotes is associated with hyperinsulinemia

de Beer, F., Stalenhoef, A. F. H., Hoogerbrugge, N., Kastelein, J. J. P., Gevers Leuven, J. A., van Duijn, C. M., Havekes, L. M., & Smelt, A. H. M. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 74

Cox proportional hazards models have more statistical power than logistic regression models in cross-sectional genetic association studies

van der Net, J. B., Janssens, A. C. J. W., Eijkemans, M. J. C., Kastelein, J. J. P., Sijbrands, E. J. G., & Steyerberg, E. W. (2008) · European Journal of Human Genetics

Genetic Associations and EpidemiologyStatistical Methods in Epidemiology

Cited by 74

FISHing for the Miracle of Eicosapentaenoic Acid

Kastelein, J. J. P., & Stroes, E. S. G. (2019) · New England Journal of Medicine

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 74

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study

Brinton, E. A., Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Braeckman, R. A., & Soni, P. N. (2013) · Cardiovascular Diabetology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 70

Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study

Arsenault, B. J., Lemieux, I., Despres, J.-P., Wareham, N. J., Luben, R., Kastelein, J. J. P., Khaw, K.-T., & Boekholdt, S. M. (2007) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 63

Physical activity, metabolic syndrome, and coronary risk: the Epic-Norfolk prospective population study

Broekhuizen, L. N., Boekholdt, S. M., Arsenault, B. J., Despres, J., Stroes, E. S., Kastelein, J. J., Khaw, K., & Wareham, N. J. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation

Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 62

Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia

Besseling, J., Reitsma, J. B., Gaudet, D., Brisson, D., Kastelein, J. J. P., Hovingh, G. K., & Hutten, B. A. (2016) · European Heart Journal

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 60

Combination statin-fibrate therapy: safety aspects

Franssen, R., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2009) · Diabetes, Obesity and Metabolism

Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug Metabolism

Cited by 60

Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT

Tietjen, I., Hovingh, G. K., Singaraja, R., Radomski, C., McEwen, J., Chan, E., Mattice, M., Legendre, A., Kastelein, J. J. P., & Hayden, M. R. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 58

Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study

Andrews, J., Janssan, A., Nguyen, T., Pisaniello, A. D., Scherer, D. J., Kastelein, J. J. P., Merkely, B., Nissen, S. E., Ray, K., Schwartz, G. G., et al. (2017) · Cardiovascular Diagnosis and Therapy

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 53

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?

Bangalore, S., Fayyad, R., Kastelein, J. J., Laskey, R., Amarenco, P., DeMicco, D. A., & Waters, D. D. (2016) · The American Journal of Medicine

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 51

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 46

A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH

Fraser, D. A., Wang, X., Lund, J., Nikolić, N., Iruarrizaga-Lejarreta, M., Skjaeret, T., Alonso, C., Kastelein, J. J. P., Rustan, A. C., Kim, Y. O., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentFatty Acid Research and Health

Cited by 41

New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing

Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 31

Non‐HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC‐Norfolk prospective population study

Sondermeijer, B. M., Rana, J. S., Arsenault, B. J., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K. (2013) · European Journal of Clinical Investigation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 30